SG11201701035SA - Cancer diagnosis and therapy - Google Patents

Cancer diagnosis and therapy

Info

Publication number
SG11201701035SA
SG11201701035SA SG11201701035SA SG11201701035SA SG11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA SG 11201701035S A SG11201701035S A SG 11201701035SA
Authority
SG
Singapore
Prior art keywords
therapy
cancer diagnosis
diagnosis
cancer
Prior art date
Application number
SG11201701035SA
Inventor
Ranui Francesca Baillie
Paul Frank Davis
Tinte Itinteang
Swee Thong Tan
Original Assignee
Gillies Mcindoe Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillies Mcindoe Res Inst filed Critical Gillies Mcindoe Res Inst
Publication of SG11201701035SA publication Critical patent/SG11201701035SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
SG11201701035SA 2014-08-12 2015-08-12 Cancer diagnosis and therapy SG11201701035SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462036583P 2014-08-12 2014-08-12
PCT/NZ2015/050108 WO2016024870A1 (en) 2014-08-12 2015-08-12 Cancer diagnosis and therapy

Publications (1)

Publication Number Publication Date
SG11201701035SA true SG11201701035SA (en) 2017-03-30

Family

ID=55304402

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901157QA SG10201901157QA (en) 2014-08-12 2015-08-12 Cancer diagnosis and therapy
SG11201701035SA SG11201701035SA (en) 2014-08-12 2015-08-12 Cancer diagnosis and therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201901157QA SG10201901157QA (en) 2014-08-12 2015-08-12 Cancer diagnosis and therapy

Country Status (12)

Country Link
US (2) US10281472B2 (en)
EP (1) EP3180000A4 (en)
JP (1) JP6899771B2 (en)
KR (1) KR20170040804A (en)
CN (1) CN106999471A (en)
AU (1) AU2015302419B2 (en)
BR (1) BR112017002724A2 (en)
CA (1) CA2957930A1 (en)
CL (1) CL2017000373A1 (en)
MX (1) MX2017001954A (en)
SG (2) SG10201901157QA (en)
WO (1) WO2016024870A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190048416A1 (en) * 2015-11-30 2019-02-14 Gillies Mcindoe Research Institute Treatment of fibrotic conditions
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
WO2017207656A1 (en) * 2016-05-31 2017-12-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system
CN110494142A (en) * 2017-01-31 2019-11-22 吉利斯麦金德研究院 Treatment of cancer
WO2019079222A1 (en) 2017-10-16 2019-04-25 Board Of Regents Of The University Of Texas System Compositions for inhibiting 3' repair exonuclease 2 and methods of screening for such compositions
JP2021500391A (en) * 2017-10-24 2021-01-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Compositions and Methods for Decreasing CD117 + Cells
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity
CN111304324B (en) * 2020-02-21 2021-05-14 温州医科大学 Application of ALPL gene as diagnosis and treatment target of lung adenocarcinoma and lung adenocarcinoma metastasis
BR112022022585A2 (en) * 2020-05-08 2022-12-13 23 Ikigai Pte Ltd METHODS FOR IDENTIFYING A MEDICAL CONDITION IN A HUMAN INDIVIDUAL
CN113069443A (en) * 2021-04-12 2021-07-06 四川大学 Application of nebivolol in preparation of medicine for preventing and/or treating oral leukoplakia and oral squamous cell carcinoma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121547A1 (en) 1991-06-28 1993-01-14 Daimler Benz Ag MULTILAYER INSULATION FILM
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6946475B1 (en) * 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
CA2895884C (en) 2000-03-06 2019-04-23 University Of Kentucky Research Foundation A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
US6605589B1 (en) * 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US6632832B1 (en) * 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
CA2521826C (en) 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
JP5662319B2 (en) * 2008-09-09 2015-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aza-benzimidazolone chymase inhibitor
EP2361988B1 (en) * 2008-10-27 2016-04-13 Sapporo Medical University Molecular marker for cancer stem cell
WO2012030234A1 (en) 2010-09-01 2012-03-08 Swee Thong Tan Methods and compositions for treating cancer
US20150125445A1 (en) * 2012-06-13 2015-05-07 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for treating cancer
WO2014205184A2 (en) * 2013-06-19 2014-12-24 University Of Miami Classification system, methods and kit for classifying. predicting and treating breast cancer

Also Published As

Publication number Publication date
US10281472B2 (en) 2019-05-07
EP3180000A1 (en) 2017-06-21
BR112017002724A2 (en) 2018-01-16
US20170234884A1 (en) 2017-08-17
JP6899771B2 (en) 2021-07-14
MX2017001954A (en) 2017-08-14
KR20170040804A (en) 2017-04-13
SG10201901157QA (en) 2019-03-28
AU2015302419B2 (en) 2021-04-01
AU2015302419A1 (en) 2017-03-09
US20200041521A1 (en) 2020-02-06
EP3180000A4 (en) 2018-03-07
CN106999471A (en) 2017-08-01
WO2016024870A1 (en) 2016-02-18
JP2017532368A (en) 2017-11-02
CL2017000373A1 (en) 2018-01-12
CA2957930A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
HK1248773A1 (en) Therapeutic and diagnostic methods for cancer
HK1250376A1 (en) Therapeutic and diagnostic methods for cancer
SG11201701035SA (en) Cancer diagnosis and therapy
GB201409363D0 (en) Skin cancer treatment
GB201401806D0 (en) Novel methods for diagnosis and therapy
GB201411884D0 (en) Cancer therapy
GB201412895D0 (en) Therapeutic and diagnostic target
GB201411818D0 (en) Therapeutic and diagnostic target
GB201404500D0 (en) Therapeutic and diagnostic target
GB201404508D0 (en) Therapeutic and diagnostic target
GB201404150D0 (en) Therapeutic and diagnostic target
GB201404137D0 (en) Therapeutic and diagnostic target
GB201404135D0 (en) Therapeutic and diagnostic target
GB201404132D0 (en) Therapeutic and diagnostic target
GB201404082D0 (en) Therapeutic and diagnostic target
GB201404087D0 (en) Therapeutic and diagnostic target
GB201403930D0 (en) Therapeutic and diagnostic target
GB201403958D0 (en) Therapeutic and diagnostic target
GB201403965D0 (en) Therapeutic and diagnostic target
GB201403450D0 (en) Therapeutic and diagnostic target
GB201403492D0 (en) Therapeutic and diagnostic target
GB201403446D0 (en) Therapeutic and diagnostic target
GB201403367D0 (en) Therapeutic and diagnostic target
GB201403364D0 (en) Therapeutic and diagnostic target
GB201403390D0 (en) Therapeutic and diagnostic target